Accelerating Innovation at Leica Biosystems

Diagnostics Overview -$9.0B TOTAL REVENUE 2021E Revenue By Mix Non-recurring BECKMAN COULTER Recurring Leica RADIOMETER® Cepheid. BIOSYSTEMS GLOBAL GROWTH DRIVERS • Penetration of molecular diagnostics By Geography By End Market • Point-of-care & decentralization of health care HGM ROW W. EU Molecular NA Core lab- Clinical All financial metrics reflect FY 2021E results from continuing operations; all pie chart percentages are % of 2021E revenues. Pathology & Other Acute Care Skilled labor shortages & cost pressures necessitating automated solutions Improving standards of care in HGM Strong global brands with leading market positions DANAHER

View entire presentation